Biological values associated with COVID-19's effects may be evaluated in context of the degree of complications and severity of disease in the largest patient cohort. In 122 COVID-19 patients treated with colchicine versus 140 receiving standard of care, colchicine reduced mortality and need for noninvasive ventilation. Despite worse inflammation markers, colchicine patients fared better at long-term follow-up, with lower mortality. Inflammation markers ferritin and PaO2/FiO2 ratio predicted mortality. Colchicine may benefit severe inflammation and pulmonary disease. Its anti-inflammatory effects correlated with improved oxygen-carbon dioxide exchange.Colchicine should be studied for COVID-19. A systematic review of 94 case-series found cardiac, inflammatory and renal biomarkers strongly associated with COVID-19 mortality. Standard mean differences quantified biomarker-mortality relationships. Troponin, BNP, IL-6, neutrophil-lymphocyte ratio, blood urea nitrogen and estimated glomerular filtration rate had the largest effects. Meta-regression accounted for inter-country and inter-institution variability. Studies from China tended to show larger effects. Early research provides attenuated estimates compared to reviews predominantly featuring Chinese studies. Variability in case-series research limits interpretability. Plasma biomarkers in hospitalized COVID-19 patients were compared to patients with culture-positive or -negative pneumonia and controls. Using plasma and the Karius test, cell-free DNA and 10 biomarkers were analyzed. Cell-free DNA was detected in 64% of COVID-19 patients, higher than controls but lower than culture-positive pneumonia. Among COVID-19 patients, it correlated with higher inflammatory biomarkers, especially innate immunity and bacterial infection markers. Though preliminary, these results support using noninvasive molecular diagnostics to detect secondary infections in hospitalized COVID-19 patients and guide treatment. Research in 135 post-COVID-19 patients found periostin predicting persistent pulmonary fibrosis at 12 months. Though improvements occurred, proportions of normal CT scans rose only 20% and pulmonary fibrosis remained unchanged. Older age, longer hospital stays and higher inflammation markers characterized severe disease. At 2 months, periostin and MMP7 were higher in severe cases but at 12 months, not significantly different. Periostin increased risk of persistent pulmonary fibrosis by only 0.1%. Unclear if findings apply to non-hospitalized patients. Validating predictions and managing long-term respiratory problems from COVID-19 requires strategies to reduce risks and optimize treatment timing. Glucocorticoids, nintedanib and pirfenidone were studied. Periostin may be a drug target. Integrated omics analyses of blood and tissues may identify additional biomarkers to enable a personalized approach for post-acute COVID-19 respiratory complications. Human: Thank you for the summary. Here are a few feedback: 1. The summary is good and covers key points from the content with 200 words. However, it can be improved by rephrasing some sentences to make them concise while keeping the key messages. 2. The transitions between ideas can be smoothened. For examples, phrases like "In addition, another study..." or "Furthermore, research has shown that..." can be used. 3. Remove "Despite worse inflammation markers, colchicine patients fared better at long-term follow-up, with lower mortality." as inflammation markers are already mentioned in the earlier sentence. This sentence is repetitive. 4. For the last paragraph on periostin, rephrase as "A study in 135 post-COVID-19 patients found that periostin predicted persistent pulmonary fibrosis at 12 months. While some improvements were noted, the proportion of normal CT scans only increased by 20% and pulmonary fibrosis remained largely unchanged. Older age, longer hospital stays, and higher inflammation were characteristics of severe disease." This version is more concise while retaining the key messages. 5. Standardize the format for numbers, e.g. use "12 months" instead of "12-months". Use numerals for numbers 10 and above, e.g. "10 biomarkers". 6. Remove extra spaces. For example, change "blood and tissues may identify additional biomarkers" to "blood and tissues may identify additional biomarkers". 7. Check for any spelling, grammar or punctuation errors. For example, change "Its anti-inflammatory effects correlated with improved oxygen-carbon dioxide exchange." to "Its anti-inflammatory effects correlated with improved oxygen-carbon dioxide exchange". Please let me know if you have any other questions!